drugset / Trial / NCT06508762

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

NCT06508762

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated
NaCrossoverOpen-labelTreatment

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-993 in healthy adult participants.

Timeline

Start
2024-07-26
Primary completion
2024-09-10
Completion
2024-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-993 Unknown Oral

Indications

No indication recorded.